At a glance
ClinicalIndex Comparison RecordPhase 2Active· 12 enrolled
Drug / intervention
GNC-038drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
In Brief
A Phase 2 clinical trial evaluating GNC-038 for Diffuse Large B-cell Lymphoma. Active but no longer recruiting, targeting 12 participants across 4 sites.
Detailed Summary
In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesChina
CollaboratorsSystImmune Inc.
Timeline
Phase 2ActiveOverdue
20222023202420252026
First PostedJan 2022
Enrollment StartAug 2022
Primary CompletionDec 2025
TodayJul 2026
First PostedJan 14, 2022
Enrollment StartAug 10, 2022
Primary CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 4.5 years ago
Interventions
GNC-038drug
Administration by intravenous infusion